Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | CDC25A | P30304 | 4/20 | 0.45 |
| ▸ | CDC25B | P30305 | 3/20 | 0.45 |
| ▸ | SRD5A1 | P18405 | 7/20 | 0.42 |
| ▸ | FNTA | P49354 | 1/20 | 0.40 |
| ▸ | FNTB | P49356 | 1/20 | 0.40 |
| ▸ | SRD5A2 | P31213 | 4/20 | 0.40 |
| ▸ | NPC1L1 | Q9UHC9 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5341638 | 0.86 | USP2 (0.49) | USP2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL5346604 | 0.86 | USP2 (0.49) | USP2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL5344359 | 0.81 | USP2 (0.64) | USP2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL5339861 | 0.81 | USP2 (0.64) | USP2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL14412753 | 0.81 | MEN1 (0.45) | USP2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL7797018 | 0.78 | MEN1 (0.68) | USP2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL1032902 | 0.78 | MEN1 (0.68) | USP2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL12884155 | 0.78 | MEN1 (0.68) | USP2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL13077330 | 0.78 | MEN1 (0.68) | USP2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL12869820 | 0.78 | MEN1 (0.68) | USP2MEN1KMT2AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1077992-A1 | MEIOSIS REGULATING COMPOUNDS | NOVO NORDISK A/S (DK) | 2001-02-28 | — | — | EP | claimed |
| WO-1999058549-A1 | MEIOSIS REGULATING COMPOUNDS | NOVO NORDISK A/S (DK) | 1999-11-18 | — | — | WO | claimed |
| EP-0957108-A1 | Unsaturated cholestane derivatives, pharmaceutical compositions comprising them and use of these derivatives for the preparation of meiosis regulating medicaments | SCHERING AKTIENGESELLSCHAFT (DE) | 1999-11-17 | — | — | EP | claimed |
| US-RE39678-E1 | Meiosis regulating compounds | NOVO NORDISK A/S (DK) | 2007-06-05 | — | — | US | disclosed |
| US-20050101573-A1 | Meiosis regulating compounds | NOVO NORDISK A/S (DK) | 2005-05-12 | — | — | US | disclosed |
| US-6884796-B2 | Meiosis regulating compounds | NOVONORDISK A/S (DK) | 2005-04-26 | — | — | US | disclosed |
| EP-1077992-B1 | USE OF MEIOSIS REGULATING COMPOUNDS | NOVO NORDISK AS (DK) | 2003-12-10 | — | — | EP | disclosed |
| US-6407086-B2 | NOVEL STEROL DERIVATIVES USED FOR REGULATING THE MEIOSIS IN OOCYTES AND IN MALE GERM CELLS | NOVO NORDISK A/S (DK) | 2002-06-18 | — | — | US | disclosed |
| US-20010003782-A1 | Meiosis regulating compounds | NOVA NORDISK A/S (DK) | 2001-06-14 | — | — | US | disclosed |
| EP-1077992-A1 | MEIOSIS REGULATING COMPOUNDS | NOVO NORDISK A/S (DK) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999058549-A1 | MEIOSIS REGULATING COMPOUNDS | NOVO NORDISK A/S (DK) | 1999-11-18 | — | — | WO | disclosed |
| EP-0957108-A1 | Unsaturated cholestane derivatives, pharmaceutical compositions comprising them and use of these derivatives for the preparation of meiosis regulating medicaments | SCHERING AKTIENGESELLSCHAFT (DE) | 1999-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010003782-A1 | Meiosis regulating compounds | SREBF2, SREBF1, TRIP13 | USP2 1879/4885MEN1 2167/4885KMT2A 1254/4885 |
| US-20050101573-A1 | Meiosis regulating compounds | SREBF2, SREBF1, TRIP13 | USP2 1879/4885MEN1 2167/4885KMT2A 1254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.